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Phospholipase D (PLD) has been implicated in the signal transduction pathways initiated by several mito-
genic protein tyrosine kinases. We demonstrate for the first time that most notably PLD2 and to a lesser extent
the PLD1 isoform are tyrosine phosphorylated by c-Src tyrosine kinase via direct association. Moreover,
epidermal growth factor induced tyrosine phosphorylation of PLD2 and its interaction with c-Src in A431 cells.
Interaction between these proteins is via the pleckstrin homology domain of PLD2 and the catalytic domain of
c-Src. Coexpression of PLD1 or PLD2 with c-Src synergistically enhances cellular proliferation compared with
expression of either molecule. While PLD activity as a lipid-hydrolyzing enzyme is not affected by c-Src, wild-
type PLDs but not catalytically inactive PLD mutants significantly increase c-Src kinase activity, up-regulating
c-Src-mediated paxillin phosphorylation and extracellular signal-regulated kinase activity. These results dem-
onstrate the critical role of PLD catalytic activity in the stimulation of Src signaling. In conclusion, we provide
the first evidence that c-Src acts as a kinase of PLD and PLD acts as an activator of c-Src. This transmodu-
lation between c-Src and PLD may contribute to the promotion of cellular proliferation via amplification of
mitogenic signaling pathways.
Phospholipase D (PLD) catalyzes the hydrolysis of phospha-
tidylcholine, the major membrane phospholipid, to form phos-
phatidic acid (PA) and choline. PA is generally recognized as
the signaling product of PLD and functions as an effector in
multiple physiological processes. The PLD pathway is thought
to play a critical role in regulating cell responses that contrib-
ute to mitotic signaling and transformation (14, 17, 23, 28, 36).
To date, two PLD isoforms have been cloned and character-
ized. PLD1 has a low basal activity and is up-regulated by small
G proteins (ARF, Rho, and Ral), protein kinase C (PKC), and
phosphatidylinositol 4, 5-bisphosphate (PIP2) in vitro. In con-
trast, PLD2 has a high basal activity, requires PIP2, and is up-
regulated by ADP-ribosylation factor and protein kinase C (6,
16). Although many studies focusing on the regulation of PLD
have been reported, the cellular role of PLD remains still
unclear.
Protein tyrosine phosphorylation is important in regulating
signaling pathways through its effects on protein-protein inter-
actions. Tyrosine kinase receptors such as epidermal growth
factor (EGF) and platelet-derived growth factor receptors
stimulate PLD activity in some cell types, suggesting that PLD
activity is modulated by tyrosine phosphorylation (2, 13, 18).
Recently, Min et al. (33) and Marcil et al. (31) reported that
pervanadate induced tyrosine phosphorylation on PLD1 in
Swiss 3T3 fibroblasts and HL60 cells, respectively. Expression
of PLD1 or PLD2 in HEK 293 cells revealed that PLD2, but
not PLD1, is constitutively associated with the EGF receptor
and becomes phosphorylated on tyrosine-11 upon stimulation
with EGF (49). Mutation of tyrosine-11 to phenylalanine did
not alter the magnitude of EGF stimulation. Thus, it was
suggested that tyrosine phosphorylation of PLD2 is important
for interaction with SH2-containing proteins but not for its
intrinsic activity as a lipid-hydrolyzing enzyme. Not only the
identity of the kinase responsible for phosphorylation of PLD
but also the role of phosphorylated PLD in cellular responses
needs to be clarified. Furthermore, in neutrophils stimulated by
fMLP (N-formyl-methionyl-leucyl-phenylalanine) and monoso-
dium urate crystals, PLD1 was activated but not tyrosine phos-
phorylated (32). Therefore, the physiological relevance of ty-
rosine phosphorylation as an activation mechanism of PLD
remains to be established.
PLD has been reported to be overexpressed and hyperacti-
vated in some human cancers (40, 54, 55, 59). Consistent with
these findings, PLD can facilitate mitogenesis and oncogenic
transformation (17, 28, 36), and protein tyrosine kinase (PTK)
activity occurs widely in mitogenic signaling (12). Jiang et al.
(20–22) demonstrated that v-Src (pp60v-src), the viral counter-
part of the nonreceptor tyrosine kinase c-Src (pp60c-src), stim-
ulated PLD activity in fibroblasts and that small G proteins Ras
and GTPase Ral were involved in PLD activation. The src
oncogene encodes a membrane-localized tyrosine-specific pro-
tein kinase whose enzymatic activity is necessary to induce
oncogenic transformation (7, 24, 42). Because the oncogenicity
of c-Src correlates with its kinase activity, the Src oncoprotein
probably induces transformation by phosphorylating critical
cellular proteins that control cell proliferation. Src kinase ac-
tivity and sometimes Src protein levels were found to be ele-
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vated in a wide variety of human cancers, with a frequent
correlation between Src kinase activity and the degree of ma-
lignancy and/or invasiveness (3, 19). Recently, it was reported
that elevated expression of PLD1 or PLD2 resulted in the
transformation of rat fibroblasts overexpressing c-Src (23).
However, little is known about how PLD cooperates with c-Src
to transform cells.
In the present study, we demonstrate that PLD associates
with c-Src. For the first time, we provide the evidence that PLD
is an effector for c-Src activation as well as a physiologically
relevant substrate by c-Src kinase. Therefore, we hypothesize
that this intimate cross talk between PLD and c-Src contributes
to cell proliferation by amplifying Src signaling pathways.
MATERIALS AND METHODS
Materials. Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine se-
rum, and Lipofectamine were purchased from Invitrogen. Protein A-Sepharose
and glutathione-Sepharose 4B were from Amersham Bioscience Biotech. Hy-
drogen peroxide and phorbol myristate acetate were from Sigma. EGF and
anti-phosphotyrosine antibody (P-Tyr) (4G10) were from Upstate Biotechnol-
ogy, and PP2 was from Calbiochem. Antipaxillin antibody was from Transduction
Laboratories (Lexington, Ky.). The antibody to c-Src was from Santa Cruz.
Phospho-Tyr416 c-Src, the activated form of the kinase (8, 10), phospho-paxillin,
phospho-ERK, and ERK were assessed by using an antibody from Cell Signaling.
A polyclonal antibody that recognizes both PLD1 and PLD2 was generated as
previously described (34). Phosphatidylbutanol (PtdBut) standard was from
Avanti Polar Lipid. [9, 10-3H]myristate was purchased from Perkin-Elmer Life
Sciences. Silica gel 60 A thin-layer chromatography plates were from Whatman.
Horseradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG) and
anti-rabbit IgG were from Kirkegaard & Perry Lab (Gaithersburg, Md.). The
ECL Western blotting detection kit was from Amersham Bioscience.
Cell culture and transfections. Human A431 epidermoid carcinoma cells were
purchased from the American Type Culture Collection. The establishment of
mouse fibroblast cells overexpressing wild-type PLD2 was described previously
(36). FaO rat hepatoma cell lines overexpressing wild-type, dominant negative
mutant, and dominant active mutant of c-Src were obtained by transfection by
using Lipofectamine according to the manufacturer’s instructions. Transfected
cells were selected with G418 (400 g/ml) for 21 days at 37°C. At that time
antibiotic-resistant colonies were pooled and expanded for further analysis under
selective conditions. COS-7 cells were transfected with human PLD1, PLD2,
catalytically inactive mutants PLD1-K898R, PLD2-K758R, N-terminally deleted
mutants of PLD2 183(184-933) and PLD2 313(314-933), Lck, Fyn, and wild-
type and mutant c-Src (K295M) expression vectors by using Lipofectamine. All
cells were maintained in DMEM supplemented with 10% fetal bovine serum.
Plasmid construction and preparation of GST fusion proteins. The c-Src
truncation mutants (SH3, SH2, or kinase domains) with coding regions corre-
sponding to amino acids 88 to 137, 144 to 245, and 265 to 523, respectively, were
created by PCR amplification. The forward primers used to amplify the trunca-
tion mutants of c-Src with coding region starting at amino acid 88, 144, or 265
were 5-CCGGAATTCATGGCTCTCTACGACTACGAGTCC-3, 5-CGGAA
TTCATGCAGGCTGAAGAGTGGTAC-3, and 5-CCGGAATTCATGGAG
TCGCTGCGGCTGGAGGTGAA-3, respectively. The reverse primers that
were used to amplify the truncation mutants of c-Src constructs that end at amino
acid 137, 245, or 523 were 5-CCGCTCGAGCTAGACATAGTTACTGGGGA
TGTA-3 , 5-CGCTCGAGTCAGCAGACGTTGGTCAGGCG-3, and 5-CC
GCTCGAGCTATGTCGAGGTGAAGTAGTCCTC-3, respectively. The PCR
fragments were then subcloned in frame with the N-terminal fusion glutathione
S-transferase (GST) at the EcoRI/XhoI site in the pGEX4T-1 vector (Amersham
Bioscience Biotech). All the constructs were sequenced to verify the coding
regions of c-Src. The full-length PLD2 and its two deletion mutants with coding
regions corresponding to amino acids 184 to 933 or 314 to 933 were created by
PCR. A cDNA fragment encoding PLD2 183(184-933) was amplified from
pcDNA3.1-PLD2 by PCR using sense (5-GAATTCATGACAGAGTTCCTGG
AAGTCAGTGC-3) and antisense (5-GCGGCCGCTATGTCCACACTTCTA
GGGGGATC-3) oligonucleotides. It was then digested with EcoRI and NotI
and ligated together with the EcoRI/NotI fragment encoding PLD2 183
(184-933) into pCMV-Flag5b (Stratagene) vector. A cDNA fragment encoding
hPLD2 313(314-933) was amplified from pcDNA3.1-PLD2 by PCR using sense
(5-GAATTCATGGGCAGAGACTTCCTACAGCTGCAC-3) and antisense
(5-CTCGAGTGTCCACACTTCTAGGGGGATC-3) oligonucleotides. The
PCR fragments were digested by EcoRI and XhoI and ligated together with the
same digestion fragment into pCMV-Flag5b expression vector. Each deletion
construct was confirmed by DNA sequencing.
PLD activity assay. PLD activity was assessed by measuring the formation of
[3H]PtdBut, the product of PLD-mediated transphosphatidylation, in the pres-
ence of 1-butanol. After 20 h of transfection with Lipofectamine, COS-7 cells in
six-well plates were serum starved in the presence of 1 Ci of [3H]myristic
acid/ml. After overnight starvation, the cells were washed three times with 5 ml
of phosphate-buffered saline (PBS) and preequilibrated in serum-free DMEM
for 1 h. For the final 10 min of preincubation, 0.3% butan-1-ol was included. At
the end of the preincubation, cells were treated with agonists for the indicated
times. The extraction and characterization of lipids by thin-layer chromatography
were performed as previously described (34).
Immunoprecipitation. Cells or tissues were washed twice with ice-cold PBS
and then lysed in the extraction buffer (20 mM HEPES [pH 7.2], 1% Triton
X-100, 1% sodium deoxycholate, 0.2% sodium dodecyl sulfate [SDS], 200 mM
NaCl, 1 mM Na3VO4, 1 mM NaF, 10% glycerol, 10 g of leupeptin/ml, 10 g of
aprotinin/ml, 1 mM phenylmethylsulfonyl fluoride). The resulting cell lysates
were spun at 15,000  g in an Eppendorf microcentrifuge for 10 min at 4°C to
pellet the unbroken cells. The supernatant was then precleared for 30 min with
preimmune IgG and protein A Sepharose at 4°C with rocking. Protein concen-
trations were determined by using the Bradford method with bovine serum
albumin as a standard (4). Equal protein aliquots of precleared cell lysates (1 mg)
were incubated with the indicated antibodies and 40 l of a 1:1 slurry of protein
A-Sepharose beads for 4 h at 4°C. The immune complexes were collected by
centrifugation, washed five times with a buffer (20 mM Tris [pH 7.5], 1 mM
EDTA, 1 mM EGTA, 150 mM NaCl, 2 mM Na3VO4, 10% glycerol, and 1%
Nonidet P-40), and resuspended in sample buffer. Immune complexes were
boiled in SDS sample buffer.
Western blotting. Protein samples were analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE) on 8% gels and were transferred to a nitrocellulose
membrane. The blots were then blocked with 5% nonfat milk and incubated with
the appropriate primary antibodies followed by incubation with horseradish
peroxidase-conjugated secondary antibody. Immunoreactive bands were de-
tected by enhanced chemiluminescence.
In vitro binding assay. Wild-type human PLD2, N-terminal 184-amino-acid-
deleted mutant PLD2 183(184-933), and the N-terminal 313-amino-acid-de-
leted mutant PLD2 313(314-933) were transfected in COS-7 cells as described
previously (1). Transfected cells were lysed in lysis buffer. After centrifugation,
aliquots of the soluble extract were coimmunoprecipitated and subjected to
immunoblot analysis by using an antibody against PLD or c-Src as described
above. After cotransfecting COS-7 cells with PLD2 and c-Src, a GST pull-down
assay was performed by using GST fusion proteins attached to glutathione-
Sepharose beads. Clarified lysates (1 mg) were incubated with 2 g of GST
fusion proteins immobilized on glutathione-Sepharose beads in a final volume of
500 l of the extraction buffer for 1 h at 4°C. Protein complexes were collected
by centrifugation and washed four times with washing buffer (1% Triton X-100,
150 mM NaCl, 20 mM Tris-HCl [pH 8.0], 20 mM NaF, 200 M sodium or-
thovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 g of leupeptin/ml, 10 g
of aprotinin/ml). Associated protein complexes were resolved by SDS-PAGE and
transferred to a nitrocellulose membrane, followed by immunoblot analysis with
anti-PLD antibody.
Generation of mouse monoclonal antibody specific for PLD2. The fragment of
PLD2 (724 to 825 amino acids) was fused to GST. For the production of
monoclonal antibody, a female BALB/c mouse (7 to 8 weeks old) was immunized
with 50 g of the purified GST fusion protein in complete Freund’s adjuvant. At
intervals of 2 weeks, three booster injections were given. Three days before cell
fusion, the mouse was further boosted by an injection of 50 g of the protein in
PBS. The spleen cells from the immunized mouse were fused with SP2 myeloma
cells. Standard fusion, screening, and cloning procedures were followed. Culture
supernatants were screened for the immunoblotting. The cells from the positive
wells were cloned twice to ensure monoclonality.
Cell viability assays. The trypan blue exclusion method was used to quantify
cell proliferation. After transfection, cells were harvested by trypsin and washed in
PBS. Trypan blue (Sigma) was added to suspended cells at a concentration of 0.4%
(wt/vol). Live cell numbers were determined by counting with a hemocytometer.
Measurement of c-Src activation. To detect activated c-Src, clarified whole-
cell lysates of transfected cells were resolved by SDS-PAGE and transferred to
nitrocellulose membranes. Tyr416-phosphorylated c-Src was detected by using a
1:1,000 dilution of anti-phospho Tyr416 c-Src antibody, with horseradish perox-
idase-conjugated goat anti-rabbit IgG as secondary antibody. Identical samples
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were immunoblotted with c-Src antibody as controls. Immune complexes on
nitrocellulose were visualized by enzyme-linked chemiluminescence.
RESULTS
Src family PTKs induce tyrosine phosphorylation of PLD
isozymes. We investigated whether the Src family PTKs were
capable of phosphorylating PLD isozymes. Cotransfection ex-
periments were performed with COS-7 cells utilizing Src family
PTKs and PLD expression vectors as depicted in Fig. 1A. After
transfection, cell lysates were prepared and subjected to im-
munoprecipitation by using an antibody directed against P-Tyr,
and tyrosine phosphorylation of PLD isozymes was monitored
by successive immunoblotting for PLD. The anti-PLD antibody
generated by us recognized both PLD1 and PLD2. The data
presented in Fig. 1A show that transfection of vectors contain-
ing c-Src, Lck, and Fyn resulted in tyrosine phosphorylation
of PLD2, while faint phosphorylation of PLD1 was observed
only after a long exposure of the membrane to film (data not
shown).
The studies that are described next were focused on c-Src,
since c-Src of the tested Src family PTKs induced the strongest
tyrosine phosphorylation of PLD. In cells cotransfected with
FIG. 1. PLD2 and, to a lesser extent, PLD1 are tyrosine phosphor-
ylated by c-Src tyrosine kinase. (A) COS-7 cells were transiently co-
transfected for 40 h with various combinations of plasmids encoding
PLD1, PLD2, c-Src, Lck, and Fyn. Cell lysates were immunoprecipi-
tated with anti-P-Tyr antibody, and precipitated proteins were sub-
jected to immunoblot analysis with an anti-PLD antibody. Western
blot analysis using PLDs and c-Src family tyrosine kinase demonstrated
that the respective proteins were expressed to equal extents. (B)
COS-7 cells were transiently transfected with the indicated expression
plasmids, and cell lysates were subjected to immunoprecipitation with
anti-P-Tyr antibody or anti-PLD antibodies. Immunoprecipitates were
separated by SDS-PAGE and immunoblotted with anti-PLD or anti-
P-Tyr antibody. Expression of PLD and c-Src was determined by using
anti-PLD or anti-c-Src antibodies. (C) COS-7 cells were transiently
transfected with various combinations of plasmids encoding PLD1,
PLD2, wild-type (WT) c-Src, and dominant negative (DN) c-Src. Cell
lysates were immunoprecipitated by using anti-P-Tyr antibody or anti-
PLD antibody, and immune complexes were analyzed by immunoblot-
ting. Immunoreactive proteins were visualized by use of horseradish
peroxidase-coupled secondary antibody and chemiluminescence. Data
are representative of three experiments.
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PLD1 or PLD2 plus c-Src, both PLD1 and PLD2 (approxi-
mately 125 and 105 kDa, respectively) were tyrosine phosphor-
ylated, whereas no tyrosine-phosphorylated proteins (except
for IgG chains) were detected in cells transfected with PLD1 or
2 plus empty vector (Fig. 1B). Similar results were obtained by
immunoblotting analysis with the antibody directed against
P-Tyr after immunoprecipitation with anti-PLD antibody.
Since equal amounts of PLD1 and PLD2 were immunoprecipi-
tated from all samples (Fig. 1B), it appears that PLD2 is
notably more strongly tyrosine phosphorylated than PLD1.
Western blot analysis showed that the 60-kDa tyrosine-phos-
phorylated protein was c-Src.
The c-Src mutant K295M is kinase inactive due to disrupted
phosphotransfer activity (9). Cotransfection of the kinase-in-
active mutant c-Src with PLDs did not lead to tyrosine phos-
phorylation of PLD1 and PLD2, whereas wild-type c-Src did
(Fig. 1C). These results indicate that both PLD1 and PLD2 are
tyrosine phosphorylated by the expression of c-Src tyrosine
kinase and that PLD2 is its preferred substrate.
PLD1 and PLD2 bind to wild-type c-Src but not to the
kinase-inactive c-Src mutant. Next, we examined whether ty-
rosine phosphorylation of PLD occurs through its direct inter-
action with c-Src having kinase activity. Cells were cotrans-
fected with PLD1 or PLD2 plus wild-type or mutant c-Src.
Coimmunoprecipitation assays indicated that both PLD1 and
PLD2 associated with wild-type c-Src, but not with the kinase-
inactive mutant (Fig. 2). PLD2, which was more strongly ty-
rosine phosphorylated by c-Src than PLD1, revealed a stronger
interaction with c-Src. These results demonstrate that the ex-
tent of phosphorylation in PLD isozymes by c-Src kinase is
closely correlated with the binding affinity between PLD iso-
zymes and c-Src protein.
EGF induces tyrosine phosphorylation of PLD2 and its as-
sociation with c-Src in A431 cells. Next, we investigated wheth-
er the interaction between Src and PLD2 could be induced by
extracellular stimuli without the enforced overexpression of
these proteins. We used A431 cells which express PLD2 iso-
zyme and EGF receptors as a model system (35). For this study
FIG. 2. PLD isozymes, most notably PLD2, bind to wild-type c-Src but not to the kinase-inactive c-Src mutant. COS-7 cells were transiently
transfected for 40 h with various combinations of plasmids encoding PLD1, PLD2, wild-type (WT) c-Src, and dominant negative (DN) c-Src. Cell
lysates were immunoprecipitated with anti-PLD or anti-c-Src antibodies, and immune complexes were subjected to immunoblotting analysis using
anti-c-Src or anti-PLD antibodies, respectively. Expressions of PLDs and c-Src were determined by immunoprecipitation and immunoblotting.
Data are representative of three experiments.
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we generated mouse monoclonal antibody specific for PLD2
but not PLD1, and this PLD2 antibody was used for immuno-
blotting due to its inability to immunoprecipitate PLD protein
(Fig. 3A). Serum-starved cultures of the cells were exposed to
EGF in the presence or absence of a selective inhibitor of Src
family tyrosine kinase, PP2, and cell lysates were prepared and
subjected to immunoprecipitation with antibody against either
P-Tyr or c-Src. Tyrosine phosphorylation of PLD2 isozyme and
its association with c-Src were monitored by successive im-
munoblotting for mouse monoclonal anti-PLD2 antibody.
As shown in Fig. 3B, EGF induced tyrosine phosphorylation
of PLD2 and pretreatment of c-Src kinase inhibitor reduced
EGF-induced tyrosine phosphorylation of PLD2. PLD2 was
associated with c-Src in response to EGF (Fig. 3B), suggesting
that interaction of PLD2 and c-Src is regulated by a physio-
logical ligand such as EGF.
The N-terminal PH domain of PLD2 is required for its
interaction with c-Src. PLD2 contains a number of functional
domains, including conserved catalytic regions (I, II, III, and
IV), a PIP2-binding site, a pleckstrin homology (PH) domain,
and an N-terminal phox (PX) domain (Fig. 4A) that has been
proposed to mediate a wide variety of protein-protein interac-
FIG. 3. EGF induces tyrosine phosphorylation of PLD2 and its association with c-Src in A431 cells. (A) Mouse monoclonal antibody specific
for PLD2 was generated as described in Materials and Methods. To analyze its specificity, PLD1 or PLD2 was transfected into COS-7 cells and
the lysates were immunoblotted with anti-PLD antibody which recognizes both PLD1 and PLD2 or anti-PLD2 antibody. (B) Quiescent A431 cells
were pretreated with or without a selective inhibitor of Src family tyrosine kinase, PP2 (2 M), for 30 min and stimulated with 200 ng of EGF/ml
for 20 min. Cell lysates were prepared, and 1 mg of the lysates were immunoprecipitated with anti-P-Tyr antibody or anti-c-Src antibody.
Immunoprecipitated proteins were separated on SDS-PAGE gel and probed with mouse monoclonal antibody specific for PLD2. The result shown
is representative of three experiments.
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tions as well as binding of phospholipids (15, 18, 56). To de-
termine the domain(s) of PLD2 required for c-Src interaction,
cells were cotransfected with an N-terminally deleted mutant
construct of PLD2, namely 183(184-933) or 313(314-933)
plus c-Src. Using an antibody to PLD that recognizes the C-
terminal region of PLD, we found that truncation of the N-
terminal 313 amino acids from PLD2 (which removes both the
PX domain and the PH domain) resulted in the loss of c-Src
association, while truncation of the N-terminal 183 amino acids
(which removes the PX domain) did not affect its association
(Fig. 4B). These data indicate that the PH domain of PLD2 is
critical for the interaction with c-Src. Moreover, using a GST
pull-down assay, we confirmed that the GST PH domain in-
teracted with c-Src (Fig. 4C).
Association of PLD2 with the kinase domain of c-Src. Hav-
ing identified the PLD2 region required for association with
c-Src, we next sought to identify the c-Src region involved in
binding to PLD2. GST fusion proteins that contained the spe-
cific domains of c-Src, namely, GST-SH3, GST-SH2, and GST-
kinase, were prepared (Fig. 5A). c-Src and PLD2 were coex-
pressed in COS-7 cells, cell lysates were prepared, incubated
with fusion proteins, and subjected to a GST pull-down
assay, and proteins were analyzed by immunoblotting with
an anti-PLD antibody. We found that the catalytic domain,
but not SH3 or SH2, was required for binding to PLD2 (Fig.
5B).
Modulation between PLD isozymes and c-Src significantly
enhances cellular proliferation. Next, we investigated the roles
of PLD and c-Src in the cellular growth. Mouse fibroblasts
overexpressing PLD1 or PLD2 (36) were plated at a density of
5  104 cells in 12-well plates and transfected with control
vector or wild-type or a kinase-inactive mutant c-Src. After
incubation for 40 h, the live cells were counted by using the
trypan blue exclusion assay. As we reported recently (36),
overexpression of PLD in the fibroblast increased growth rates
compared to those of vector-transfected cells. Cells transfected
with wild-type c-Src displayed increased cell proliferation com-
pared to cells transfected with the control vector or the kinase-
FIG. 4. The N-terminal PH domain of PLD2 is required for inter-
action with c-Src. (A) Schematic representation of PLD2. The boxes in-
dicate highly conserved sequences of PLD; their possible functions have
been proposed or demonstrated in reference 52. CR, conserved region.
(B) COS-7 cells were transiently cotransfected with plasmids encoding
the empty vector (Vec) and c-Src, or PLD2 and c-Src, or N-terminal
183-amino-acid-truncated PLD2 183(184-933) and c-Src, or N-termi-
nal 313-amino-acid-truncated PLD2 313(314-933) and c-Src. Cell
lysates were subjected to immunoprecipitation by using anti-PLD or
anti-c-Src antibodies, and the amount of coimmunoprecipitated c-Src
or PLD was determined by immunoblotting with anti-c-Src or anti-
PLD antibodies. Expression of PLD2 and c-Src was determined by us-
ing anti-PLD or anti-c-Src antibodies. (C) For the GST pull-down assay,
GST-PH fusion protein was used as described in reference 29. The ly-
sates transfected with c-Src were incubated with 2 g of GST or GST-
PH fragment and immunoblotted with antibody to c-Src. The amount
of the GST fusion proteins was visualized by immunoblotting with an
anti-GST antibody. Data are representative of three experiments.
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inactive mutant (Fig. 6). Coexpression of c-Src and PLD1 or 2
synergistically increased the cellular proliferation over that
observed with expression of either molecule. Cells proliferated
even at high density, suggesting that these cells overcame den-
sity arrest. These results based on the number of cells were
similar to those obtained from the proliferation assay based on
metabolic conversion of a tetrazolium compound, MTS (3-
[4,5-dimethylthiazol-2-yl]-5-[3-carboxylmethoxylphenyl]-2-[4-
sulfophenyl]-2H-tetrazolium), to a colored product by living
cells (data not shown). These results demonstrate that modu-
lation between PLD2 and c-Src might contribute to enhanced
cellular proliferation.
Tyrosine phosphorylation of PLD by c-Src does not affect its
phospholipase activity. Next, we attempted to examine the
underlying mechanisms of the modulation between PLD and
c-Src, possibly leading to enhancement of cellular prolifera-
tion. We first investigated whether PLD phosphorylation by
c-Src has any effect on its phospholipase activity. Constitutively
active c-Src mutant was coexpressed with PLD1 or 2 in COS-7
cells, and in vivo PLD activity was measured following EGF
stimulation. The results of these experiments showed that
EGF-induced PLD activity in cells cotransfected with PLD1 or
2 plus constitutively active c-Src was similar to that in cells
cotransfected with PLDs plus control vector (Fig. 7A). Tran-
sient expression of the dominant negative mutant c-Src also did
not affect PLD activity (data not shown). Similar data were
obtained by using FaO hepatoma cells stably overexpressing
the constitutively active mutant c-Src, in which EGF-induced
PLD activity was not different from that in cells expressing
empty vector or inactive c-Src (Fig. 7B). These results suggest
that tyrosine phosphorylation of PLD by c-Src does not in-
crease its phospholipase activity. Therefore, other regulatory
mechanism(s) contributing to the promotion of cellular prolif-
eration by interaction between PLD and c-Src may exist.
Stimulation of c-Src kinase activity by PLD. Next, we inves-
tigated whether PLD might lead to an increase in Src kinase
activity. It has become clear that autophosphorylation of Tyr416
in the activation loop is critical for full activation of Src-family
tyrosine kinases (26, 53, 57). First, COS-7 cells were transiently
cotransfected with c-Src and various PLD2 constructs, and the
lysates were assayed for c-Src activity by immunoblotting with
an antibody specific for c-Src autophosphorylated at Tyr416
(anti-phospho-Y416 c-Src [37]). The data presented in Fig. 9A
show that cells coexpressing wild-type PLD2 and c-Src con-
tained high levels of autophosphorylated kinase. Truncation of
the N-terminal region containing the PX and PH domains of
PLD2 (which eliminates 85% of the basal activity) resulted in
decreased c-Src activation, whereas truncation of the N-termi-
nal 183 amino acids from PLD2 (which removes the PX do-
mains but still yields a catalytically active enzymes) induced an
activation of c-Src similar to that in cells transfected with
wild-type PLD2 and c-Src (Fig. 8A). Since the N-terminal
FIG. 5. The catalytic domain of c-Src interacts with PLD2. (A)
Schematic representation of GST-fusion protein constructs. (B) c-Src
was fragmented into SH3 (88-137), SH2 (144-245), and kinase (265-
523) domains. The fragments were cloned as GST fusion proteins,
expressed in Escherichia coli, and purified by use of glutathione-con-
jugated Sepharose beads. An equal amount (2 g) of GST or GST-Src
fragment was incubated with the lysates of COS-7 cells transfected
with PLD2 and c-Src. The pull-down proteins were subjected to im-
munoblot analysis with an antibody against PLD (upper panel). The
amount of the GST fusion proteins was visualized by immunoblotting
with an anti-GST antibody (lower panel). Data are representative of
three experiments.
FIG. 6. Modulation between PLD2 and c-Src significantly en-
hances cellular proliferation. Mouse fibroblasts overexpressing PLD
isozymes were plated at a density of 5  104 cells in 12-well plates and
transfected with empty vector (Vec), wild-type (WT) c-Src, or domi-
nant negative (DN) c-Src mutant. After 40 h of incubation, viable cells
were counted by a trypan blue exclusion method. Results show means
 standard deviations of three independent experiments.
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313-amino-acid-truncated PLD2 mutant that does not bind to
c-Src (PLD2 313(314-933) failed to activate c-Src (Fig. 4B),
we further examined whether PLD catalytic activity or the
binding of PLD isozyme with c-Src is more critical for c-Src
activation by PLD isozyme. Vector or PLD alone did not
induce autophosphorylation of Tyr416 in transfected cells. In-
terestingly, not only wild-type PLD2 but also wild-type PLD1
significantly stimulated c-Src kinase activity compared to cells
transfected with c-Src alone. In contrast, both catalytically in-
active mutants of PLD1 and PLD2 reduced c-Src kinase activ-
ity (Fig. 8B). As shown in Fig. 2, PLD1 has a much lower
binding affinity with c-Src than does PLD2. Furthermore, a
catalytically inactive PLD2 mutant also interacted with c-Src to
the same extent as wild-type PLD2 (Fig. 8C). These results
demonstrate that the catalytic activity of PLD isozyme rather
than its binding with c-Src is required for c-Src activation by
PLD.
Not only c-Src-induced tyrosine phosphorylation of paxillin
but also ERK activation is potentiated by expression of PLD
isozymes. c-Src has been reported to phosphorylate paxillin in
integrin signaling or various mitogenic signaling pathways (58).
Therefore, we investigated whether PLD affects c-Src-induced
phosphorylation of paxillin. Transient cotransfection of c-Src
and PLD into COS-7 cells showed that overexpression of wild-
type PLDs, but not catalytically inactive mutant PLDs, in-
creased tyrosine phosphorylation of paxillin compared to cells
expressing c-Src and empty vector (Fig. 9). Tyrosine phosphor-
ylation of paxillin was not detected in cells transfected with
vector or PLD only. This result suggests that PLD with a
catalytic activity might be involved in the potentiation of ty-
rosine phosphorylation of paxillin, possibly through activation
of c-Src. In addition, it has been reported that overexpression
or activation of c-Src is involved in the activation of the Ras/
ERK pathway in COS-7 cells (29). Using phospho-specific
antibodies that bind only activated forms of ERK, we exam-
ined whether PLD enhanced c-Src-stimulated ERK activity.
Transient expression of wild-type PLD1 or PLD2 plus c-Src
resulted in increased ERK activity compared to that observed
with cells transfected with c-Src and empty vector or catalyti-
cally inactive PLD mutant plus c-Src (Fig. 9). Activation of
ERK was not detected in cells transfected with vector or PLD
only. Taken together, these results suggest that activation of
the Src signaling cascade is also dependent upon PLD activity.
DISCUSSION
It has recently become apparent that PLD activity plays a
significant role in transduction of intracellular signals (11, 27,
51). Since tyrosine kinases have been shown to form networks
with a diverse array of cellular signal transduction pathways, a
PLD-tyrosine kinase link provides novel mechanisms for PLD
signaling to modulate a broad range of physiological responses.
Therefore, it is crucial to understand how these two signaling
components communicate with each other.
Several studies indicate that PTKs participate in the PLD
activation via an unidentified mechanism (38). However, the
biological significance of phosphorylation as one of the activa-
tion mechanisms of PLD still remains to be determined, since
PLD activity has not been correlated with its phosphorylation
level in many studies (18, 32). In addition, the nature of the
tyrosine kinase has not yet been defined. Recent studies dem-
onstrated that PLD1 and PLD2 were phosphorylated in cell-
free preparations by p38MAP kinase (39) but such phosphor-
ylation did not enhance PLD activity. It was suggested that an
ERK-dependent tyrosine kinase might mediate the effect of
norepinephrine on tyrosine phosphorylation of PLD2 (41).
Although PLD is phosphorylated on serine and threonine res-
idues in intact cells in response to phorbol myristate acetate
(25) or on tyrosine residues by pervanadate (31, 33), it is still
unclear whether this phosphorylation of PLD is of physiolog-
ical relevance to enhanced hydrolysis of phosphatidylcholine
or other phospholipid substrates.
Although Src tyrosine kinase has been shown to play a role
in PLD-mediated signaling (23, 43), the link between c-Src and
PLD was not clear. In this study, we demonstrate for the first
FIG. 7. c-Src does not affect EGF-induced PLD activation in
COS-7 and FaO cells. COS-7 cells transiently transfected with various
constructs (A) and FaO cells expressing constitutive active c-Src
(Y529F) or dominant inactive c-Src mutant (K296R/Y528F) (B) were
labeled with [3H]myristic acid for 18 h. The cells were untreated or
treated with 200 ng of EGF/ml for 30 min in the presence of 0.3%
1-butanol. Radioactivity incorporated into PtdBut was measured as
described in Materials and Methods. *, P  0.05 compared to cells
transfected with vector and treated with EGF. Results show means 
standard deviations of three independent experiments.
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time that Src family protein kinases induced tyrosine phos-
phorylation of PLD isozymes, most notably PLD2, by transient
transfection. Moreover, EGF induced tyrosine phosphoryla-
tion of PLD2 in A431 cells. However, EGF-induced PLD ac-
tivity was not altered by coexpression of c-Src in COS-7 cells.
In addition, EGF-induced PLD activity in hepatoma cells over-
expressing constitutive active mutant c-Src was not different
from the activity shown in cells transfected with empty vector
or dominant inactive c-Src. These results suggest that tyrosine
phosphorylation of PLD by c-Src does not increase PLD phos-
pholipase activity. This correlates with a previous report that
overexpression of active c-Src or kinase-negative mutant c-Src
did not affect PLD activity in rat mesangial cells (44) but is in
contrast to observations with fibroblasts transformed by the
viral counterpart and oncogenic PTK v-Src (20). A comparison
of the effects of pp60c-src and pp60v-src would suggest that only
the oncogenic tyrosine kinase is able to interfere with the Ras
pathway. The significance of PLD activation by v-src tyrosine
kinase is unknown. Moreover, the molecular basis by which
PLD activity is differentially regulated by v-Src and c-Src re-
mains to be clarified. In some pathways, the enzymatic activity
of PLD as a lipid hydrolytic enzyme might not be strictly
required for PLD function, pointing to the multifaceted nature
of the PLD protein. Consistent with this hypothesis, it was
reported that the mitogenic activity of phospholipase C-1,
which is known to play an important role in cell proliferation,
does not exclusively result from the enzymatic activity of the
lipase and that another activity inherent to the phospholipase
C-1 molecule can also induce DNA synthesis in quiescent
cells (50). Although it is possible that nonphospholipase activ-
ities of PLD through tyrosine phosphorylation play a role in
PLD-mediated cellular signaling, at present it is still not clear
how tyrosine phosphorylation of PLD contributes to PLD-
mediated signal transduction in cells. Tyrosine phosphoryla-
FIG. 8. Overexpression of PLD stimulates c-Src kinase activity. (A)
COS-7 cells were transiently cotransfected with various combinations
of plasmids encoding empty vector (Vec) and c-Src, or PLD2 and
c-Src, or N-terminal 183-amino-acid-truncated PLD2 183(184-933)
and c-Src, or N-terminal 313-amino-acid-truncated PLD2 313(314-
933) and c-Src. Cell lysates were subjected to immunoblot analysis
using a phospho Tyr416 c-Src antibody. Expression of c-Src was deter-
mined by using an anti-c-Src antibody. (B) COS-7 cells were transiently
transfected for 40 h with various combinations of plasmids encoding an
empty vector, PLD1, PLD2, c-Src, and c-Src plus either wild-type (wt)
or catalytically inactive mutant (mt) PLD1 or PLD2. Data are repre-
sentative of three experiments. (C) COS-7 cells were transiently co-
transfected with a catalytically inactive PLD2 mutant and wild-type
c-Src, and cell lysates were subjected to immunoprecipitation with
anti-c-Src antibody or anti-PLD antibodies. Immunoprecipitates were
separated by SDS-PAGE and immunoblotted with anti-PLD or anti-
c-Src antibody. Expression of PLD and c-Src was determined by using
anti-PLD or anti-c-Src antibodies. Data are representative of three
experiments.
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tion of PLD may not be critical for proliferation because PLD1
and PLD2 show enhancement in a similar potency prolifera-
tion by coexpression of c-Src synergistically, even though the
extent of tyrosine phosphorylation of PLD1 is very different
from that of PLD2. We cannot exclude the possibility that
tyrosine-phosphorylated residues in PLD2 by c-Src may pro-
vide the docking sites to recruit the proteins with the SH2
domain, leading to amplification of Src signaling cascades. The
biological significance of PLD tyrosine phosphorylation re-
mains to be determined in detail.
PLD associated with c-Src, and it was the catalytic domain,
not the SH3 and SH2 domains, of c-Src that was required for
binding to PLD2. This is reminiscent of the interaction of G	s
and G	i with the catalytic domain of c-Src (30). c-Src binds to
a region of PLD2 containing PH, which is known to be in-
volved in protein-protein interactions as well as binding of
phospholipids (56). Highly tyrosine-phosphorylated PLD2 was
strongly associated with c-Src in cotransfection experiments.
This was comparable to EGF-induced association of phosphor-
ylated PLD2 with c-Src in A431 cells.
To understand PLD signaling and its biological functions, it
is essential to identify the direct targets of PLD. The effectors
of PLD might be proteins interacting with it or the signaling
molecules that are activated by PA. Therefore, we investigated
the possibility that PLD has a role not only as a substrate of
c-Src but also as a regulator of c-Src. Coexpression of wild-type
PLD1 or PLD2, but not catalytically inactive PLD mutants,
along with c-Src, stimulated c-Src kinase activity. There seems
to be little difference between PLD1 and PLD2 in c-Src acti-
vation, even though the extent of their interaction with c-Src is
very different. Although catalytically inactive PLD mutant as-
sociated with c-Src, overexpression of the PLD mutant rather
decreased c-Src activation. Therefore, c-Src activation via PLD
appeared to be dependent upon the catalytic activity of PLD
rather than interaction of PLD with c-Src. The present work
identifies PLD as a regulator of Src family tyrosine kinases and
provides substantial new insights for future investigations in
the two fields of PLD function and Src regulators.
Until now, PLDs have not been studied for their ability to
increase c-Src kinase activity. In the present study, we demon-
strate for the first time that there is an intimate cross-regula-
tion between PLD and c-Src. Critical downstream targets of
the Src kinase remain controversial and probably depend on
the particular signaling pathway that activated the kinase.
Many proposed substrates of c-Src are derived from studies of
proteins phosphorylated by the activated viral Src protein, such
as phosphatidylinositol 3 kinase, Shc, phospholipase C-, pax-
illin, vinculin, and ERK (5, 29, 48). In the present study, we
demonstrated that PLD-induced activation of c-Src increased
tyrosine phosphorylation of paxillin and activation of ERK,
downstream target molecules of Src. Activation of these mol-
ecules was also dependent on the catalytic activity of PLD. Our
FIG. 9. PLD enhances not only c-Src-induced tyrosine phosphorylation of paxillin but also c-Src-mediated ERK activation. COS-7 cells were
transiently cotransfected for 40 h with various combinations of plasmids encoding an empty vector, PLD1, PLD2, c-Src, and c-Src plus either
wild-type (wt) or catalytically inactive mutant (mt) PLD1 or PLD2. Cell lysates were immunoblotted with an antibody directed against tyrosine-
phosphorylated paxillin (A) or an anti-phospho-ERK antibody (B). Expression of total paxillin and ERK was visualized by immunoblotting with
antipaxillin antibody or anti-ERK antibody. Data are representative of three experiments. The intensity of phosphorylated paxillin or phospho-
ERK immunoreactive bands quantified by densitometry of immunoblot was expressed as relative intensity of the bands. Results show means 
standard deviations of three independent experiments.
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observations are consistent with the recent report demonstrat-
ing that EGF-induced ERK activation is dependent upon PLD
activity in A431 cells (46). This may occur by stimulation of
c-Src signaling via PLD activity-dependent mechanism. There-
fore, our results suggested that PA generated by PLD activity
might be involved in the c-Src/ERK pathway. A number of
studies have demonstrated that PA induces tyrosine phosphor-
ylation in neutrophils and other cell types (45, 47). While it is
tempting to speculate that PA-dependent tyrosine phosphory-
lation may be involved in activation of c-Src and stimulation of
the ERK, additional experiments are required to prove this
hypothesis.
Both PLD and c-Src are overexpressed and highly activated
in a wide variety of human cancers (19, 40, 54, 55, 59). A
connection between activation of Src via PLD and cancer pro-
gression would be a significant finding. Consistent with such a
connection, Joseph et al. (23) reported that elevated expres-
sion of either PLD1 or PLD2 transformed cells overexpressing
c-Src. Therefore, it is reasonable to propose that these two
proteins have coordinated functions.
The present studies significantly advance our understanding
of the cross talk between PLDs and c-Src tyrosine kinases. In
summary, our novel findings show that there is an interaction
between Src and PLD protein leading to tyrosine phosphory-
lation of both PLD1 and PLD2 and that this interaction and
PLD activity activate c-Src, leading to autophosphorylation,
paxillin phosphorylation, and ERK activation. PLD is tyrosine
phosphorylated as a novel substrate of c-Src and stimulates Src
kinase signaling in a PLD activity-dependent mechanism, in-
ducing cell proliferation (Fig. 10). These characteristics sug-
gest that PLD lies at an interesting nexus of Src-dependent
signaling. Further studies aimed at the elucidation of cell
growth signal 3 c-Src 3 signaling event of PLD phosphory-
lation and PLD-stimulated c-Src downstream signaling events
leading to the gene expression are necessary to gain a better
understanding of the functional role of PLD in mediating sig-
nals from c-Src tyrosine kinase.
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